TIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insight 2028 Report Highlights:
- Insight on Emerging TIM3 Inhibitors in Development As Monotherapy & combination Therapy
- Future Market Opportunity Insight From First Drug Approval: 2024 – 2028
- Insight On TIM3 Inhibitors Drug In clinical Trials: > 15 Drugs
- TIM3 Inhibitors Drug In Clinical Trials Insight By Country, Company, Indication
- Comprehensive Clinical Insight On Biomarker Identified During Clinical Trials
- TIM3 Targeted Therapy Application By Various Cancers
Immunotherapy has emerged out to be breakthrough therapy in the management of cancer due to its responsiveness observed in cancer patients. Although this therapeutic approach has shown promising implications in the clinic, this treatment’s relative responsiveness has limitations thus far reduced its effectiveness to use in small subsets of patients within a larger cohort. To mitigate these limitations, several combination immunotherapeutic approaches have been introduced. The combination cancer immunotherapy combines two or more drugs which have synergistic mechanism of action and can overcome the drug resistance.
The progress in the field of genomics and proteomics has led to identification of new therapeutic targets for the management of cancer. Recently, researchers have identified the therapeutic potential of T-cell immunoglobulin mucin-3 (TIM-3) immune checkpoint receptor for the treatment of wide range of cancers including acute myeloid leukemia, melanoma, gastric cancer, head and neck cancer, lung cancer, and others. Further, studies have also shown that the expression of TIM-3 is correlated with programmed cell death-1 (PD-1) receptor, thus suggesting its potential role in combination immunotherapy. This has led to flurry of investments by pharmaceutical companies to initiate preclinical and clinical studies evaluating the response of TIM-3 in combination with PD-1 or other cancer targeting regimens.
Currently, no TIM-3 inhibitor has gain market authorization but several others are present in clinical pipeline suggesting promising future of the market. The pipeline of TIM-3 inhibitor consists of several potential candidates including MBG453, TSR-22, Sym023, LY3321367, BGB-A425, BMS-986258, and others. These drugs are rapidly demonstrating encouraging response which suggests promising response of these drugs in cancer immunotherapy market. For instance, Sabatolimab (MBG453) has shown encouraging response in the management of acute myeloid leukemia when utilized in combination with either hypomethylating agents (azacitidine or decitabine). On the basis of these encouraging results, the drug has received fast track designation from US FDA as well as orphan drug status from European Union, and is thus expected to gain market authorization by 2024.
In addition to this, several other TIM-3 inhibitors are also being evaluated in early stages of clinical development. For instance, Incyte Corporation has developed INCAGN02390 which is fully human Fc engineered IgG1kappa monoclonal antibody against TIM-3. Currently, the company is conducting phase-I/II clinical trial evaluating the combination of INCAGN02390 and INCAGN02385 (LAG-3 antibody) with/without INCMGA00012 (Anti-PD-1). Further, Chia Tai Tianqing Pharmaceutical Group has also initiated phase-I clinical trial evaluating the TQB2618 injection (TIM-3 monoclonal antibody) in combination with Terprizumab injection. The large number of ongoing clinical trial suggests the promising future of TIM-3 combination therapy in the management of cancer.
It is suggested that US will be major market for the development of TIM-3 inhibitors during the forecast period. This is mainly due to early adoption of targeted therapy in the region associated with favorable government policies boosting the research and development activities. In addition, presence of large pharmaceutical market and research centers in the region also propels the clinical trials in this region. Apart from this, China will also emerged as potential market owing to large investments by domestic Chinese pharmaceutical companies.
The global market will mainly be restricted by the long duration of drug development and stringent regulatory guidelines. However, as the healthcare sector of majority regions is shifting towards novel therapeutic approach the drug regulatory bodies are providing special provisions and rapid approvals are expected in coming years. Moreover, rising occurrence of different forms of cancer, technological advancements in the field of immune-oncology for cancer treatment, and rising awareness concerning the benefits of targeted therapies over conventional cancer therapies will also propel the growth of market.